BreakingNVAX
Novavax (NVAX) Stock Soars 16% After an Analyst Rating Change
Novavax shares rose 15.8% as MT Newswires reported: BofA Adjusts Price Target on Novavax to $8 From $7, Keeps Underperform Rating
Shares of Novavax Inc. (NVAX) rose 15.8% to $12.75 in the session of Monday, October 12, on volume of 19.03M shares.
The move came as MT Newswires reported: BofA Adjusts Price Target on Novavax to $8 From $7, Keeps Underperform Rating.
Other coverage:
- BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push (Stocktwits)
- Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies (24/7 Wall St.)
- Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
What the GTA data shows
- Market value: about $2.1B · Health Care.
Written by the GTA Research Desk from GTA Terminal data. Not investment advice.
FREE NEWSLETTER
Get stories like this in your inbox
The market's biggest stories each morning, plus what options traders, insiders and Congress are doing with their money. Free.